A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs NGM 831 (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors NGM Biopharmaceuticals

12 Feb 2024 Planned number of patients changed from 79 to 130.
12 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Mar 2026.
12 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com